Laronde Stock
Laronde develops an eRNA-based therapeutic platform that is capable of indicating diverse proteins inside the body.
Sign up today and learn more about Laronde Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Laronde Stock
Laronde develops an eRNA-based therapeutic platform that is capable of indicating diverse proteins inside the body. It is persistent, non-immunogenic, allows for repeat dosing, and offers flexibility in formulation and delivery. Laronde was founded in 2017 by Flagship Labs, the innovation foundry of Flagship Pioneering. The company is rapidly scaling to support the parallel development of multiple programs across many disease areas.
Funding History
| 2021-05-01 | $50.0M |
|---|---|
| 2021-08-01 | $440M |
Management
Co-founder and Chairman of the Board
Noubar Afeyan
Co-founder & Board of Directors
Avak Kahvejian
Board of Directors
Noubar Afeyan
Chief Operating Officer
Tej Pavoor
Chief Technology Officer
Vadim Dudkin
Head of Manufacturing
Tushar Misra
CEO
Diego Miralles
Chief Scientific Officer
Jesper Gromada
Press
statnews - Jun, 19 2023
Listen: Biogen’s messy board, Laronde’s data problem, & the downside of a boombizjournals - May, 11 2023
The Petri Dish: Laronde CEO exits after 6 months; Enanta seeks Covid pill partnerpharmiweb - May, 8 2023
Laronde Announces New Leadershipbiospace - Nov, 17 2022
Laronde Appoints Pablo J. Cagnoni as Chief Executive Officerprnewswire - Aug, 4 2022
Laronde Appoints John Mendlein as Chief Executive Officernews - Nov, 29 2021
These Are The Industries Where Series B Funding Is Growing Fastestnews - Oct, 7 2021
North American Startup Funding Remained Really, Really High In Q3ow - Sep, 14 2021
Circle Line: Laronde’s “Endless” RNA Draws $440M from Investorsthemiddlemarket - Aug, 31 2021
Laronde, Backed by Moderna Creator, Raises $440Mfiercebiotech - Aug, 30 2021
Laronde banks $440M to ramp up RNA-based meds that could turn cells into protein factoriesprnewswire - Aug, 30 2021
Laronde Attracts $440M in First External Financing to Further Advance Endless RNA™ Platformfinsmes - Aug, 30 2021
Laronde Raises $440M in Series B FinancingEquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
